Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness

This article was originally published in The Tan Sheet

Executive Summary

Separation of its women's health, nutritional supplement and clinical diagnostic businesses to create new publicly traded company owned by Inverness shareholders announced by Waltham, Mass.-based firm May 23. J&J will acquire Inverness' diabetes care business in a stock-for-stock exchange valued at roughly $1.3 bil. New firm likely will be led by current management team and will retain $40 mil. in cash following spin-off. Transaction awaits Inverness shareholder approval and is expected to close in fourth quarter. Inverness products include Smart Care vitamin and mineral supplement brand sold online and in Wal-Mart, CVS, Walgreens
Advertisement

Related Content

Inverness Medical Innovations
Inverness Medical Innovations
Inverness Medical Innovations

Topics

Advertisement
UsernamePublicRestriction

Register

PS092594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel